1-3 of 3
Xiaobin Zhao
Close
Sort by
Journal Articles

FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma

Qing Liu, Xiaobin Zhao, Frank Frissora, Yihui Ma, Ramasamy Santhanam, David Jarjoura, Amy Lehman, Danilo Perrotti, Ching-Shih Chen, James T. Dalton, Natarajan Muthusamy, John C. Byrd
Journal: Blood
Blood (2008) 111 (1): 275–284.
https://doi.org/10.1182/blood-2006-10-053884
Published: 2008
Journal Articles

Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical

Xiaobin Zhao, Rosa Lapalombella, Trupti Joshi, Carolyn Cheney, Aruna Gowda, Martha S. Hayden-Ledbetter, Peter R. Baum, Thomas S. Lin, David Jarjoura, Amy Lehman, Donna Kussewitt, Robert J. Lee, Michael A. Caligiuri, Susheela Tridandapani, Natarajan Muthusamy, John C. Byrd
Journal: Blood
Blood (2007) 110 (7): 2569–2577.
https://doi.org/10.1182/blood-2006-12-062927
Published: 2007
Journal Articles

FTY720 (2-Amino-2-[2-(4-octylphenyl) ethyl] Propane 1, 3-diol hydrochloride), Mediates Cytotoxicity through Caspase Independent and Protein Phosphatase 2A Dependent Mechanisms in Chronic Lymphocytic Leukemia and Lymphoblastic Leukemia/Lymphoma.

Qing Liu, MS, Xiaobin Zhao, M.S., Frank Frissora, M.S., Yihui Ma, M.S., Ramasamy Santhanam, Ph.D., Danilo Perrotti, M.D.,Ph.D., Ching-Shih Chen, Ph.D., James T. Dalton, Ph.D., John C. Byrd, M.D., Natarajan Muthusamy, DVM.,Ph.D.
Journal: Blood
Blood (2006) 108 (11): 2095.
https://doi.org/10.1182/blood.V108.11.2095.2095
Published: 2006